<p><strong>Aim.</strong> Endoscopic surgery demonstrates promising results of treatment in patients with non-paroxysmal atrial fibrillation. Minimally invasive thoracoscopic ablation contributes to the growing interest in such operations all over the world. Nowadays totally thoracoscopic ablations are available for patients in Russian Federation. Emphasis in our study was placed on the collection and analysis of data on thoracoscopic ablation procedures used for treating patients with lone atrial fibrillation.</p><p><strong>Methods.</strong> The study covered the operations performed by Russian cardiac surgeons over a period up until January 1, 2018. Data collection was based on emailed registration forms containing information about the date of procedures, type of ablation pattern, previous catheter procedures, used devices, methods of left atrial appendage closure and safety profile information. 30-day mortality, conversion to sternotomy/thoracotomy, stroke/ transient ischemic attack, reexplorations, cardiac tamponade and phrenic nerve damage were considered as major complications.</p><p><strong>Results</strong>. The study encompassed 10 cardiosurgical centers in Russian Federation where totally thoracoscopic ablations had been carried out between 2011– 2018. Six hundred fifty-two procedures were registered. Most patients were ablated in Dallas and Box Lesion patterns. Left atrial appendage exclusion was performed in 90,4% patients. Major complications were observed in 27 (4%) patients, mostly during the “learning curve” period.</p><p><strong>Conclusion.</strong> The given study is the first attempt to collect and systematize the data on a new surgical procedure for treatment of patients with atrial fibrillation. The data obtained allow for making a conclusion that thoracoscopic ablation is becoming a wide-spread surgical technique to treat patients with lone atrial fibrillation in Russia. The quantity of procedure increases annually. Introducing thoracoscopic procedures in clinical practice may be accompanied by complications at any center. Nevertheless, according to our investigation the rate of complications is low, which enables us to recommend thoracoscopic ablation to treat a numerous cohort of atrial fibrillation patients in Russia.</p><p>Received 13 June 2018. Revised 22 July 2018. Accepted 23 July 2018.</p><p><strong>Funding:</strong> The study did not have sponsorship.</p><p><strong>Conflict of interest:</strong> Authors declare no conflict of interest.</p>
ПИДАНОВ ОЛЕГ ЮРЬЕВИЧ, канд. мед. наук, врач сердечно-сосудистый хирург отделения кардиохирургии ФГБУ «Клиническая больница» Управления делами Президента Российской Федерации, Россия, 107150, Москва, ул. Лосиноостровская, 45, e-mail: 9681@mail.ru Реферат. Цель исследования -оценка портативной системы CardioQVARK в качестве инструмента для мо-ниторинга состояния сердечно-сосудистой системы у пациентов после торакоскопической абляции по поводу фибрилляции предсердий. Материал и методы. В исследование включены 8 пациентов, оперированных по поводу симптомной формы фибрилляции предсердий (EHRA III-IV). Всем пациентам выполнялась торакоско-пическая фрагментация левого предсердия по схеме Dallas Lesion Set стандартным набором радиочастотных инструментов. У пациентов в стационарных условиях с 1-й по 5-й день после операции регистрировались записи 5-минутных электрокардиограмм при помощи портативного монитора CardioQVARK с передачей данных по сети интернет мобильного оператора через облачный сервис в приложение CardioQvark Doctor. Результаты и их обсуждение. При сравнении с показаниями прикроватного монитора значимых расхождений по верификации сердечного ритма не отмечено. Стационарный этап показал удобство и простоту применения персонального монитора CardioQVARK при наблюдении за пациентами в послеоперационном периоде после хирургического лечения фибрилляции предсердий. У одного пациента в раннем послеоперационном периоде развился при-ступ типичного трепетания предсердий, верифицированный при помощи портативного монитора CardioQVARK. Выводы. Первый опыт применения персонального мониторинга на основе устройства CardioQVARK показал надежность работы прибора в условиях стационара. Применение удаленного мониторинга при помощи устрой-ства CardioQVARK позволяет вести длительное наблюдение за пациентами; эффективность дистанционного метода должна быть оценена на большом количестве пациентов. Russia, 107150, Moscow, Losinoostrovskaya str., 45, e-mail: 9681@mail.ru Abstract. Aim. CardioQVARK portable device has been assessed as a tool for cardiovascular system monitoring in patients after thoracoscopic ablation for atrial fibrillation. Material and methods. 8 patients operated for symptomatic type of atrial fibrillation (EHRA III-IV) were incorporated in the research. All patients have undergone thoracoscopic fragmentation of the left atrium according to the Dallas Lesion Set chart with standard set of radio-frequency appliance. 5 minute ECG recording with CardioQVARK device has been performed in hospital patients from the 1st to the 5th day after the surgery. CardioQVARK system provided data transmission to CardioQVARK Doctor app. by mobile internet via cloud service. Results and discussion. Significant difference in cardiac rhythm verification between CardioQVARK data and bedside monitor indication was not observed. CardioQVARK personal device has demonstrated convenience and ease of use when monitoring patients in the period after surgical treatment for atrial fibrillation in hospital setting. One patient experienced a...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.